GlobeNewswire

Volta Finance Limited : Dividend Declaration

Share

Volta FinanceLimited (VTA/VTAS)

Dividend Declaration

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION,
IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES

Guernsey, 15 September 2021

Volta Finance Limited ("the Company") hereby announces a third interim dividend for the financial year commencing 1 August 2020. 

The Company announces that it has declared a quarterly interim dividend of €0.14 per share payable on 30 September 2021 amounting to approximately €5.12 million, equating approximately to an annualised 8% of net asset value. The ex-dividend date is 23 September 2021 with a record date of 24 September 2021.

The Company has arranged for its shareholders to be able to elect to receive their dividends in either Euros or Pounds Sterling.   Shareholders will, by default, receive their dividends in Euros, unless they have instructed the Company’s Registrar, Computershare Investor Services (Guernsey) Limited (“Computershare”), to pay dividends in Pounds Sterling.  Such instructions may be given to Computershare either electronically via CREST or by using the Currency Election Form which has been posted to shareholders and a copy of which is also available on the website www.voltafinance.com within the “Investors – Other Documents” section. The deadline for receipt of currency elections is 12:00 (midday) on 27 September 2021.

For further information, please contact:

For the Investment Manager
AXA Investment Managers Paris
Serge Demay
serge.demay@axa-im.com

+33 (0) 1 44 45 84 47

Company Secretary and Administrator
BNP Paribas Securities Services S.C.A, Guernsey Branch
guernsey.bp2s.volta.cosec@bnpparibas.com
+44 (0) 1481 750 853

Corporate Broker
Cenkos Securities plc
Andrew Worne
Daniel Balabanoff
Will Talkington
+44 (0) 20 7397 8900

*****
ABOUT VOLTA FINANCE LIMITED

Volta Finance Limited is incorporated in Guernsey under The Companies (Guernsey) Law, 2008 (as amended) and listed on Euronext Amsterdam and the London Stock Exchange's Main Market for listed securities. Volta’s home member state for the purposes of the EU Transparency Directive is the Netherlands. As such, Volta is subject to regulation and supervision by the AFM, being the regulator for financial markets in the Netherlands.

Volta’s investment objectives are to preserve capital across the credit cycle and to provide a stable stream of income to its shareholders through dividends. Volta seeks to attain its investment objectives predominantly through diversified investments in structured finance assets. The assets that the Company may invest in either directly or indirectly include, but are not limited to: corporate credits; sovereign and quasi-sovereign debt; residential mortgage loans; and, automobile loans. The Company’s approach to investment is through vehicles and arrangements that essentially provide leveraged exposure to portfolios of such underlying assets. The Company has appointed AXA Investment Managers Paris an investment management company with a division specialised in structured credit, for the investment management of all its assets.

*****

ABOUT AXA INVESTMENT MANAGERS
AXA Investment Managers (AXA IM) is a multi-expert asset management company within the AXA Group, a global leader in financial protection and wealth management. AXA IM is one of the largest European-based asset managers with 753 investment professionals and €801 billion in assets under management as of the end of April 2021.

*****

This press release is published by AXA Investment Managers Paris (“AXA IM”), in its capacity as alternative investment fund manager (within the meaning of Directive 2011/61/EU, the “AIFM Directive”) of Volta Finance Limited (the "Volta Finance") whose portfolio is managed by AXA IM.

This press release is for information only and does not constitute an invitation or inducement to acquire shares in Volta Finance. Its circulation may be prohibited in certain jurisdictions and no recipient may circulate copies of this document in breach of such limitations or restrictions. This document is not an offer for sale of the securities referred to herein in the United States or to persons who are “U.S. persons” for purposes of Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or otherwise in circumstances where such offer would be restricted by applicable law. Such securities may not be sold in the United States absent registration or an exemption from registration from the Securities Act. Volta Finance does not intend to register any portion of the offer of such securities in the United States or to conduct a public offering of such securities in the United States.

*****

This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Past performance cannot be relied on as a guide to future performance.

*****
This press release contains statements that are, or may deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "anticipated", "expects", "intends", "is/are expected", "may", "will" or "should". They include the statements regarding the level of the dividend, the current market context and its impact on the long-term return of Volta Finance's investments. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Volta Finance's actual results, portfolio composition and performance may differ materially from the impression created by the forward-looking statements. AXA IM does not undertake any obligation to publicly update or revise forward-looking statements.

Any target information is based on certain assumptions as to future events which may not prove to be realised. Due to the uncertainty surrounding these future events, the targets are not intended to be and should not be regarded as profits or earnings or any other type of forecasts. There can be no assurance that any of these targets will be achieved. In addition, no assurance can be given that the investment objective will be achieved.

The figures provided that relate to past months or years and past performance cannot be relied on as a guide to future performance or construed as a reliable indicator as to future performance. Throughout this review, the citation of specific trades or strategies is intended to illustrate some of the investment methodologies and philosophies of Volta Finance, as implemented by AXA IM. The historical success or AXA IM’s belief in the future success, of any of these trades or strategies is not indicative of, and has no bearing on, future results.

The valuation of financial assets can vary significantly from the prices that the AXA IM could obtain if it sought to liquidate the positions on behalf of the Volta Finance due to market conditions and general economic environment. Such valuations do not constitute a fairness or similar opinion and should not be regarded as such.

Editor: AXA INVESTMENT MANAGERS PARIS, a company incorporated under the laws of France, having its registered office located at Tour Majunga, 6, Place de la Pyramide - 92800 Puteaux. AXA IMP is authorized by the Autorité des Marchés Financiers under registration number GP92008 as an alternative investment fund manager within the meaning of the AIFM Directive.

*****

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

After safety review The Connection study is now again open to recruit the smallest infants.22.9.2021 22:30:00 CEST | Press release

After safety review The Connection study is now again open to recruit the smallest infants. Following the completion of the DMC (Data Monitoring Committee) safety review, IBT is pleased to announce the continuation of the recruitment of patients between 500 - 1000g (Strata A and B) in the Connection study. “Given the vulnerability of the Stratum A population, infants with a birth weight less than 750 gram, we have agreed with the FDA to carefully monitor the safety of these infants. Therefore, the independent DMC has completed an additional safety review, and there are no objections to continue the study. We expect recruitment to increase as we now again recruit in two strata. ” Says Staffan Strömberg, Chief Executive Officer of IBT. About Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s Class B shares are listed on Nasdaq Stockholm, Mid-cap (IBT B). Infant Bacterial Therapeutics AB (publ) (“IBT”) is a p

Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits.22.9.2021 22:30:00 CEST | Pressemelding

Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits. Efter att säkerhetsgranskningen som utförts av Data Monitoring Committee (DMC) har slutförts kan IBT nu lämna det glädjande beskedet att rekryteringen av spädbarn i båda viktgrupperna, 500–1000 gram (Strata A och B), kan fortsätta. ”Med anledning av att spädbarnen i stratum A, som har en födelsevikt på mindre än 750 gram, är mycket känsliga har vi enats med FDA om att övervaka säkerheten för dessa spädbarn mycket noggrant. Den oberoende DMC har med anledning av detta slutfört en extra säkerhetsgranskning där det inte föreligger några invändningar mot att fortsätta studien. Vi förväntar oss att rekryteringstakten kommer att öka när vi återigen kan rekrytera i två strata. ” säger Staffan Strömberg, VD för IBT. Om Infant Bacterial Therapeutics AB Infant Bacterial Therapeutics AB (”IBT”) är ett publikt bolag med säte i Stockholm. Bolagets aktier av serie B handlas på Nasdaq Stockholm, Mid

Weekly share repurchase program transaction details22.9.2021 19:34:35 CEST | Press release

September 22, 2021 SBM Offshore reports the transaction details related to its EUR150 million (c. US$180 million) share repurchase program for the period September 16, 2021 through September 22, 2021. The repurchases were made under the EUR150 million share repurchase program announced on and effective from August 5, 2021. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period August 5, 2021 through September 22, 2021 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase Program Overall progress Share Repurchase Program: Total Repurchase Amount EUR 150,0

21Shares Announces Listing of Six Additional Crypto ETPs on Deutsche Boerse XETRA22.9.2021 19:11:35 CEST | Press release

Firm is first and only to give investors access to 10 crypto listings in Germany September 22, 2021 – 21Shares AG (“21Shares”), the world’s largest issuer of cryptocurrency ETPs, today announced the listing of six additional cryptocurrency ETPs for a total of 10 on Deutsche Boerse XETRA, Germany’s top trading venue for exchange traded funds. The new crypto ETPs include Solana ETP (Ticker: 21XL GY), Polkadot ETP (Ticker: PDOT GY), Cardano ETP (Ticker: DADA GY), Stellar Lumens ETP (Ticker: XLME GY), Tezos (Ticker: 21XZ GY), and the Crypto Basket Index ETP (Ticker:21XH GY). Hany Rashwan, Co-Founder and CEO of 21Shares said, “We are pleased to expand crypto investment opportunities in Germany, as one of our key markets, where we are the first and only firm providing such a comprehensive product suite. This development underscores our commitment to helping investors safely access crypto assets, now and in the future.” The six Xetra-listed crypto ETPs emphasize 21Shares’ leadership in crypto

Regarding public information about Klaipeda Prosecutor Office civil claim concerning AB “Klaipedos nafta” shares granted to employees22.9.2021 18:03:11 CEST | Press release

Public sources of information provided that the Klaipeda Prosecutor Office has submitted a civil claim against AB "Klaipedos nafta" (KN) on a ground of protection of public interest. As suggested by the media, a civil claim is concerning shares granted to employees in 2019. KN granted the shares to employees in 2019 according to the Rules for granting shares, which were approved in the general shareholders meeting. Relevant link: https://view.news.eu.nasdaq.com/view?id=b4561c449403dd0740cf7ee2c12302f9d&lang=en KN has not received a civil claim, thus is unable to provide any comments on the issue. Chief Financial Officer Mindaugas Kvekšas, +370 614 82665

Touax: H1 2021 results22.9.2021 17:45:00 CEST | Press release

PRESS RELEASE Paris, 22 September 2021 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION H1 2021 results Restated revenue from activities of €52.5 million, up €1.2 millionResilient business performance with EBITDA of €21.3 million and the Group share of net income amounting to €2.0 millionFavourable outlook with strong investments Touax Group continued to deliver a positive performance while the health crisis caused further disruption. Its results were stable against the same period in 2020, with the exception of sales fees, which declined but were partially offset by sales of owned equipment. The growth in the shipping container leasing business, driven by the shortage of containers, limited asset returns and therefore sales of used containers and sales fees. ANALYSIS OF H1 2021 REVENUE FROM ACTIVITIES The restated presentation of revenue from activities is as follows: Restated Revenue from activities (in € thousand)Q1 2021Q2 2021H1 2021Q1 2020Q2 2020H1 2020

Bolder Surgical announces global launch of the CoolSeal™ Vessel Sealing Platform22.9.2021 16:44:21 CEST | Press release

CoolSeal receives CE mark, Japan PMDA approval; now available in over 20 countries worldwide LOUISVILLE, COLORADO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bolder Surgical today announced the global launch of its CoolSeal™ Vessel Sealing platform. CoolSeal has been in use since October 2020 in the U.S., and with the new international regulatory approvals the devices are available in over 20 countries around the world. Bolder Surgical provides surgeons precision electrosurgical instruments to perform minimally invasive surgery safely and effectively in pediatric and adult procedures including general, gynecological and bariatric surgical applications. The CoolSeal Vessel Sealing suite includes the 3 mm Mini (formerly JustRight Sealer) and the 5 mm Trinity Sealer/Divider/Dissector. Both devices are powered with the gold-standard efficacy of advanced bipolar RF vessel sealing technology. “Having successfully used the 3 mm vessel sealer for many cases in pediatric surgery, the Trinity 5 mm devic